# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123570
Filing Date
2024-11-08
Accepted
2024-11-07 17:59:11
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nktr-20240930.htm iXBRL | 10-Q | 2246073
2 | EX-31.1 | nktr-ex31_1.htm | EX-31.1 | 13897
3 | EX-31.2 | nktr-ex31_2.htm | EX-31.2 | 14107
4 | EX-32.1 | nktr-ex32_1.htm | EX-32.1 | 9595
| Complete submission text file | 0000950170-24-123570.txt |  | 8620623

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nktr-20240930.xsd | EX-101.SCH | 1102727
61 | EXTRACTED XBRL INSTANCE DOCUMENT | nktr-20240930_htm.xml | XML | 1648091

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 241437388
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)